EGF and non-small cell lung carcinoma: The present study was designed as a phase IV trial to characterize the safety and effectiveness of CIMAvax-EGF in IIIB/IV NSCLC patients treated in 119 community polyclinics (primary healthcare institutions) and 24 hospitals (secondary healthcare institutions) of Cuba.